Please join us on the evening of the 24th May 2023, to review BeiGene’s development program including an in depth look at our research activities in either haematology or solid tumours.

This will occur from 7pm-8:30pm (AEST). This will be 5pm-6:30pm in Singapore (GMT+8)

Dr Lai Wang Ph D, Global Head of R&D for BeiGene will introduce the session and provide an overview of our research activities. Following this you have the option of 2 parallel sessions, a more in-depth review of our research activities in Haematology or Solid Tumours presented by senior members of our development team.

Dr Mehrdad Mobasher, M.D., M.P.H., is the Chief Medical Officer for Hematology and will provide a more in-depth review of our research activities in haem malignancies.

Dr Mark Lanasa MD PhD, Chief Medical Officer, Immuno- Oncology will provide a more in depth review of our research activities in solid tumours.

BeiGene Aus Pty Ltd ACN 164 802 037

Suite 11.01, Level 11, 66 Goulburn Street, Sydney, NSW 2000, Australia

Date of preparation: March 2023. 0323--MRC-135

BeiGene Singapore Pte Ltd

38 Beach Road #29 - 11, South Beach Tower, Singapore 189767

Date of preparation: March 2023. 0323--MRC-136